Surface Oncology to Participate in the H.C. Wainwright Global Healthcare Conference
Surface Oncology (Nasdaq: SURF) announced that CEO Jeff Goater and CMO Robert Ross will participate in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Surface Oncology (Nasdaq: SURF) announced that CEO Jeff Goater and CMO Robert Ross will participate in the H.C. Wainwright Global Healthcare Conference on September 14-15, 2020. They will discuss the company's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), along with their emerging pre-clinical pipeline, including SRF813 (targeting CD112R, aka PVRIG). Surface is focused on developing next-generation immunotherapies that target the tumor microenvironment, aiming to achieve sustained anti-tumor responses.
Details
News Market Reaction – SURF
The recorded move for SURF in the trading session of this news was -1.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will participate in the upcoming H.C. Wainwright Global Healthcare Conference held on September 14/15, 2020, discussing Surface Oncology's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27) as well as Surface’s emerging pre-clinical pipeline, highlighted by SRF813 (targeting CD112R, aka PVRIG).
About Surface Oncology:
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), a clinical-stage collaboration with Novartis targeting CD73 (NZV930), and two preclinical programs, each focused primarily on activating natural killer cells (via targeting CD112R, also known as PVRIG (SRF813)) or depleting regulatory T cells (via targeting CCR8 (SRF114)). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Contacts:
Investors
Matt Lane
matt@gilmartinir.com
617-901-7698
Media
Tom Donovan
tom@tenbridgecommunications.com
857-559-3397
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.